A recent study has shown that prostate cancer stem cells (PCSCs) have an enhanced tendency to be chemoresistant and may be a prognostic factor for prostate cancer recurrence; the activated STAT3 modulates chemoresistance in PCSCs by protecting autophagy and regulating MDR1 on the surface of PCSCs, which sheds new light on the selective targeted therapy against PCSCs (Talukdar et al., 2020). This evidence concerns the gene STAT3 and prostate cancer.